Cite
HARVARD Citation
Calmy, A. et al. (2020). Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet. 7 (10), pp. e677-e687. [Online].